JP2004507440A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004507440A5 JP2004507440A5 JP2001519909A JP2001519909A JP2004507440A5 JP 2004507440 A5 JP2004507440 A5 JP 2004507440A5 JP 2001519909 A JP2001519909 A JP 2001519909A JP 2001519909 A JP2001519909 A JP 2001519909A JP 2004507440 A5 JP2004507440 A5 JP 2004507440A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- resistant
- penicillin
- pathogen
- sensitive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 description 10
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- 229960003405 ciprofloxacin Drugs 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 229960003170 gemifloxacin Drugs 0.000 description 2
- -1 gemifloxacin compound Chemical class 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000018406 regulation of metabolic process Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
Applications Claiming Priority (36)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15183599P | 1999-09-01 | 1999-09-01 | |
| US15183699P | 1999-09-01 | 1999-09-01 | |
| US15191799P | 1999-09-01 | 1999-09-01 | |
| US15183499P | 1999-09-01 | 1999-09-01 | |
| US15183799P | 1999-09-01 | 1999-09-01 | |
| US15196099P | 1999-09-01 | 1999-09-01 | |
| US15388499P | 1999-09-14 | 1999-09-14 | |
| US15411599P | 1999-09-14 | 1999-09-14 | |
| US15533899P | 1999-09-22 | 1999-09-22 | |
| US15515099P | 1999-09-22 | 1999-09-22 | |
| US15514999P | 1999-09-22 | 1999-09-22 | |
| US15535899P | 1999-09-22 | 1999-09-22 | |
| US15539199P | 1999-09-22 | 1999-09-22 | |
| US15539299P | 1999-09-22 | 1999-09-22 | |
| US15538499P | 1999-09-22 | 1999-09-22 | |
| US15539399P | 1999-09-22 | 1999-09-22 | |
| US15534999P | 1999-09-22 | 1999-09-22 | |
| US15534699P | 1999-09-22 | 1999-09-22 | |
| US15534899P | 1999-09-22 | 1999-09-22 | |
| US15536099P | 1999-09-22 | 1999-09-22 | |
| US15538199P | 1999-09-22 | 1999-09-22 | |
| US15535999P | 1999-09-22 | 1999-09-22 | |
| US15534499P | 1999-09-22 | 1999-09-22 | |
| US15539499P | 1999-09-22 | 1999-09-22 | |
| US15538399P | 1999-09-22 | 1999-09-22 | |
| US15514899P | 1999-09-22 | 1999-09-22 | |
| US15537999P | 1999-09-22 | 1999-09-22 | |
| US15534799P | 1999-09-22 | 1999-09-22 | |
| US15539599P | 1999-09-22 | 1999-09-22 | |
| US15538099P | 1999-09-22 | 1999-09-22 | |
| US15534099P | 1999-09-22 | 1999-09-22 | |
| US15538299P | 1999-09-22 | 1999-09-22 | |
| US15595799P | 1999-09-24 | 1999-09-24 | |
| US15586899P | 1999-09-24 | 1999-09-24 | |
| US15586999P | 1999-09-24 | 1999-09-24 | |
| PCT/US2000/023883 WO2001015695A1 (en) | 1999-09-01 | 2000-08-31 | Methods of use of fluoroquinolone compounds against bacteria |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004507440A JP2004507440A (ja) | 2004-03-11 |
| JP2004507440A5 true JP2004507440A5 (enrdf_load_html_response) | 2007-10-18 |
Family
ID=27586941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001519909A Pending JP2004507440A (ja) | 1999-09-01 | 2000-08-31 | 細菌に対するフルオロキノロン化合物の使用法 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1401440A4 (enrdf_load_html_response) |
| JP (1) | JP2004507440A (enrdf_load_html_response) |
| AU (1) | AU6947900A (enrdf_load_html_response) |
| WO (1) | WO2001015695A1 (enrdf_load_html_response) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9920917D0 (en) | 1999-09-03 | 1999-11-10 | Sb Pharmco Inc | Novel process |
| GB9920919D0 (en) | 1999-09-03 | 1999-11-10 | Sb Pharmco Inc | Novel compound |
| ATE410225T1 (de) | 2001-08-02 | 2008-10-15 | Lg Life Sciences Ltd | Verfahren zur herstellung von amino-geschützten 4-aminomethylene-pyrrolidin-3-on-derivaten, gemifloxacin und deren salze |
| KR100517638B1 (ko) | 2002-04-08 | 2005-09-28 | 주식회사 엘지생명과학 | 게미플록사신 산염의 새로운 제조방법 |
-
2000
- 2000-08-31 AU AU69479/00A patent/AU6947900A/en not_active Abandoned
- 2000-08-31 WO PCT/US2000/023883 patent/WO2001015695A1/en active Application Filing
- 2000-08-31 EP EP00993844A patent/EP1401440A4/en not_active Withdrawn
- 2000-08-31 JP JP2001519909A patent/JP2004507440A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gendron et al. | The oral cavity as a reservoir of bacterial pathogens for focal infections | |
| WO2000010582A3 (en) | Probiotic, lactic acid-producing bacteria and uses thereof | |
| EP1194525B1 (en) | Combination of lactic acid bacteria and its use for the prevention and/or treatment of infections and inflammatory conditions | |
| RU2011129693A (ru) | Композиции и способы улучшения здоровья полости рта | |
| Herzon | Bacteremia and local infections with nasal packing | |
| JP2002522464A5 (enrdf_load_html_response) | ||
| Pajukanta et al. | In vitro antimicrobial susceptibility of different serotypes of Actinobacillus actinomycetemcomitans | |
| Brook | Pathogenicity of the Bacteroides fragilis group | |
| Brauner et al. | Occurrence of P-fimbriated Escherichia coli in patients with bacteremia | |
| JP2004507440A5 (enrdf_load_html_response) | ||
| Otani et al. | In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone | |
| Fernandez et al. | Failure of rifampin to eradicate group B streptococcal colonization in infants | |
| Ahmed et al. | Biofilm formation and autoinducer‐2 signaling in Streptococcus intermedius: role of thermal and pH factors | |
| DE69419782D1 (de) | Multimeres alpha-lactalbumin enthaltende antibakterielle zusammensetzung | |
| CA2200054A1 (en) | Use of antibodies to block the effects of gram-positive bacteria and mycobacteria | |
| Freeman | Short-term adverse effects of antibiotic prophylaxis for open-heart surgery. | |
| Guze et al. | The role of antibiotic tolerance in the response to treatment of pyelonephritis due to Staphylococcus aureus in rats | |
| Caufield et al. | In vitro susceptibility of Streptococcus mutans 6715 to iodine and sodium fluoride, singly and in combination, at various pH values | |
| Bystedt et al. | Ecological effects of penicillin prophylaxis in orthognatic surgery | |
| Ginsburg | Streptococcus. | |
| Odenholt et al. | Studies of the killing kinetics of benzylpenicillin, cefuroxime, azithromycin, and sparfloxacin on bacteria in the postantibiotic phase | |
| Kavi et al. | Intraperitoneal penetration of cefpirome | |
| Fik et al. | The Composition of the Microbiotes of the Neck Part of the Teeth in the Area of the Gum Edge of Rats at the End of the Second, Fourth and Sixth Weeks of Opioid Influence | |
| Catherall et al. | Efficacy of ticarcillin-clavulanic acid for treatment of experimental Staphylococcus aureus endocarditis in rats | |
| Sato et al. | Timing of penicillin treatment influences the course of Streptococcus pneumoniae-induced middle ear inflammation |